Notice of NIMH Participation in PAR-16-106 "Rapid Assessment of Zika Virus (ZIKV) Complications (R21)"

Notice Number: NOT-MH-16-012

Key Dates
Release Date:   May 16, 2016

Related Announcements
PAR-16-106  

Issued by
National Institute of Mental Health (NIMH)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH) is participating in PAR-16-106 ”Rapid Assessment of Zika Virus (ZIKV) Complications (R21)." 

NIMH encourages translational research on the neurodevelopmental consequences in infants of exposure to Zika Virus (ZIKV) during pregnancy or the early postnatal period.  Specifically, NIMH places high priority on understanding the potential for ZIKV to alter the developing central nervous system and social, cognitive, emotional, and behavioral outcomes relevant to mental health.  NIMH will accept applications to this FOA in accordance with standard referral guidelines among participating institutes.  Applicants are encouraged to discuss their research plans with an NIMH Program Officer before submission.

Areas of high priority for NIMH include, but are not limited to, the following: 

  • Studies to understand the mechanisms by which ZIKV affects the developing nervous system in infants, particularly in brain regions associated with social, cognitive, or affective function that is relevant to psychopathology
  • Studies to identify risk for psychopathology in infants infected with ZIKV as well as potential sequelae in exposed but uninfected infants
  • Studies to assess and characterize the natural history and long-term neurodevelopmental consequences of ZIKV infection in children on social, cognitive, and affective function in children that is relevant to mental illness
  • Investigations of mediating and moderating factors affecting variability in neurodevelopmental, behavioral, and socio-emotional impact of ZIKV exposure on infants prenatally and postnatally
  • Studies to characterize how variation in the timing of ZIKV exposure impacts neurodevelopmental outcomes and risk for psychopathology

The following sections of PAR-16-106 have been updated to reflect the participation of NIMH in this Funding Opportunity Announcement (FOA).

Part 1. Overview Information

Components of Participating Organizations

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Eye Institute (NEI)
National Institute of Biomedical Imaging (NIBIB)
National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Numbers
93.865, 93.286; 93.856; 93.855; 93.867; 93.853; 93.121; 93.839, 93.351, 93.242

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Julia L. Zehr, Ph. D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-1617
Email: zehrj@mail.nih.gov

Peer Review Contact(s)

David Armstrong, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-3534
Email: armstrda@mail.nih.gov

Financial/Grants Management Contact(s)

Tamara Kees
National Institute of Mental Health (NIMH)
Telephone: 301-443-8811
Email: tkees@mail.nih.gov

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Julia L. Zehr, Ph. D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-1617
Email: zehrj@mail.nih.gov